News | April 25, 2013

Medical Therapy Versus Angioplasty in Treating Stable Coronary Artery Disease

Population Health Management Medical Therapy Angioplasty Coronary Artery Disease

April 25, 2013 — The decision to perform an invasive procedure to open clogged arteries in the heart instead of first trying medication and lifestyle changes may not reduce a patient's risk of death or of a major cardiac event. Unnecessary procedures to treat chronic, stable heart disease contribute to rising healthcare costs. A targeted approach to avoiding this kind of overutilization by instead relying on evidence-based decision-making is presented in the peer-review journal Population Health Management. The article is available free on the Population Health Management website.

Lisa Behnke, M.D., MHA, BSN and coauthors from OptumHealth Care Solutions (Fort Myers, Fla., and Golden Valley, Minn.) and Jefferson School of Population Health (Philadelphia, Pa.) emphasize that whereas percutaneous coronary intervention (PCI) may be a lifesaving procedure for patients with an acute coronary event, it may not be more beneficial in stable coronary artery disease than more conservative treatment approaches, yet it has become increasingly common over the past 30 years.

In the article "A Targeted Approach to Reducing Overutilization: Use of Percutaneous Coronary Intervention in Stable Coronary Artery Disease," the authors present a model for shared decision-making in which physicians and patients together consider the various treatment options, what each involves, their risks and a comparison of the outcomes associated with each according to the latest evidence published in the medical literature.

"This study is a prime example of how comparative effectiveness research offers the promise of improved quality and safety, as well as lower cost," says Editor-in-Chief David B. Nash, M.D., MBA, dean and Dr. Raymond C. and Doris N. Grandon professor, Jefferson School of Population Health, Philadelphia, Pa. "Better informed decisions means the right treatments will be given to the right patients. This means fewer complications and shorter hospitalizations."

For more information: www.liebertpub.com/bari 


Related Content

News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Subscribe Now